Sensus Healthcare, Inc. is a medical device company that provides non invasive treatment options for non melanoma skin cancer and for preventing keloid scars after surgery. The company’s core technology is superficial radiation therapy known as SRT which delivers low energy X ray beams to the skin surface. Sensus has developed a family of SRT based devices including the SRT 100 the SRT 100 plus and the SRT 100 Vision. As of the end of 2025 the company had installed 955 units in 21 countries with the majority located in the United States. In addition to hardware the firm offers service programs such as the Sentinel maintenance plan and the Fair Deal Agreement revenue sharing model. The business was founded in 2010 and incorporated in Delaware before completing its initial public offering in 2016. Sensus continues to invest in research and development to expand its product portfolio and to improve patient access to non invasive skin cancer care.

Sensus Healthcare, Inc. generates revenue primarily from the sale of its SRT based radiation therapy systems. The company also earns income from service agreements that cover maintenance training and technical support. Under the Fair Deal Agreement model Sensus receives a percentage of the reimbursement collected by customers for SRT procedures. Additional revenue streams include financing programs that help customers acquire equipment and the sale of consumables such as disposable shielding and applicator tips. The firm serves private dermatology practices radiation oncology departments and other medical providers that seek non invasive skin treatment options. Service contracts provide recurring revenue streams that help stabilize cash flow. The company also generates income from the sale of consumable items such as disposable lead shielding and applicator tips that are used during each treatment session.

The company operates through the following segments.

• Single Operating Segment: this segment encompasses the design manufacture marketing and servicing of superficial radiation therapy devices and related healthcare services. Activities include the production of the SRT 100 the SRT 100 plus and the SRT 100 Vision systems the delivery of the Sentinel service program the administration of the Fair Deal Agreement revenue sharing model and the provision of financing solutions through Sensus Healthcare Financial Services.

Sensus Healthcare, Inc. occupies a niche position in the medical device market as a provider of superficial radiation therapy for skin conditions. The company competes with larger radiation equipment manufacturers that offer linear accelerator based systems and with manufacturers of alternative skin cancer treatments such as topical therapies and surgical devices. Sensus differentiates itself through its non invasive approach its low operating costs and its strong clinical evidence base that shows effective treatment outcomes for difficult to treat lesions. The firm also benefits from a growing reimbursement environment and from patents that protect its core technology. The company’s devices are designed for ease of use with automatic setup and user friendly interfaces which reduce the need for extensive training. Sensus also benefits from a strong intellectual property portfolio that includes multiple patents covering its SRT technology and related workflow management systems.

Sensus Healthcare, Inc. serves private dermatology clinics radiation oncology practices and other medical providers that treat skin lesions. The company’s customers include independent physician offices group practices and hospital based departments across the United States and in select international markets. The firm also works with distributors and resellers that help place its systems in regions outside of North America. Outside of the United States the company has placed systems in countries across Europe Asia and Latin America through a network of third party distributors. These international customers value the portability and low maintenance requirements of the SRT systems.